Belladonna and Opium Suppository shortage
To Be Discontinued 4 presentations · 1 manufacturers · first FDA posting 2026-07-23 · last update 2026-07-23
Manufacturers: Padagis US LLC
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-04) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/23/2026 Updated 07/23/2026 Discontinued 07/23/2026 |
| Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-12) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/23/2026 Updated 07/23/2026 Discontinued 07/23/2026 |
| Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-04) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/23/2026 Updated 07/23/2026 Discontinued 07/23/2026 |
| Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-12) | Padagis US LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/23/2026 Updated 07/23/2026 Discontinued 07/23/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)